Effective August 19, 2026, European cell bank FamiCord AG will transfer its stock exchange listing from the regulated Prime Standard market to the Scale segment of the Frankfurt Stock Exchange Open Market. Approved by Deutsche Börse AG, the move aims to reduce regulatory complexity while keeping ticker symbols and shares unchanged.
The strategic shift follows a resolution made on June 29, 2026, by the Management Board of FamiCord AG. According to corporate statements reported via EQS News and ad-hoc-news.de, the transition is enabled by the Act to Strengthen Germany as a Financial Centre (Standortförderungsgesetz – StoFöG). This statutory framework allows for a simplified transfer from the regulated market to an SME growth market under Article 33 of Directive 2014/65/EU.
In Plain English: The Clinical Takeaway
- FamiCord AG, recognized as Europe’s leading cell bank and third largest globally, is altering how its corporate stock is traded to streamline administrative overhead.
- Biological storage operations—including cryopreservation of umbilical cord blood and postnatal tissue—remain fully active.
- No new shares are issued during this segment transfer.
Financial Restructuring and Operational Focus at FamiCord AG
Operating out of Leipzig since 1997—originally founded as Vita 34—FamiCord has built a repository of well over one million stored biological units from customers across around 50 countries. The company functions as a full-service provider for cryopreservation, handling collection, logistics, processing, and long-term storage of stem cells from umbilical cord blood and cord tissue in the vapor phase of liquid nitrogen.
Jakub Baran, CEO of FamiCord AG, noted via corporate disclosures that the prior listing requirements within the Prime Standard no longer matched the proportional benefits for the company’s current structure. “With the transfer to Scale, we are creating a capital markets framework that is better aligned with the size and structure of FamiCord AG,” Baran stated. He added that shares will remain publicly tradable on the Frankfurt Stock Exchange while freeing operational resources to focus on core cell banking and Cell and Gene CDMO (Contract Development and Manufacturing Organization) activities.
Regulatory Frameworks and Market Impact
The transition highlights a move by FamiCord to optimize administrative burdens under modern SME regulations. By shifting to the Frankfurt Open Market’s Scale segment, FamiCord reduces compliance costs traditionally mandated by prime standard regulations.
Postnatal stem cells are utilized both directly as medicinal products and as foundational starting materials for medical cell therapies.
| Metric | Previous Designation | New Designation |
|---|---|---|
| Exchange Market | Regulated Market (Prime Standard) | Scale Segment (Open Market) |
| Effective Date | Last trading day: August 18, 2026 | First trading day: August 19, 2026 |
| Identifiers | ISIN, WKN, Ticker Symbol | Unchanged |
| Issuance | N/A | No new shares issued |
Contraindications & When to Consult a Doctor
References
- Deutsche Börse AG. Frankfurt Stock Exchange Scale Market Guidelines and Regulations.
- Directive 2014/65/EU of the European Parliament and of the Council on markets in financial instruments (MiFID II).
- Act to Strengthen Germany as a Financial Centre (Standortförderungsgesetz – StoFöG). Federal Law Gazette of Germany.
Disclaimer: This article is for informational purposes only and does not constitute financial advice or medical recommendation.
